1. Feng YX, Jin DX, Sokol ES, Reinhardt F, Miller DH, Gupta PB. 2017. Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1. Nature Communications8:1079
2. Sokol ES*, Feng YX*, Jin DX*, Tizabi MD, Miller DH, et al. 2017. SMARCE1 is required for the invasive progression of in situ cancers. PNAS114:4153-8 (*co-first author)
3. Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, et al. 2014. Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress. Cancer Discovery 4:702-15
4. Feng YX, Sokol ES, Gupta PB. 2014. The endoplasmic reticulum may be an Achilles' heel of cancer cells that have undergone an epithelial-to-mesenchymal transition. Molecular & Cellular Oncology 1:e961822
5. Feng YX, Wang T, Deng YZ, Yang P, Li JJ, et al. 2011. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 53:483-92
6. Feng YX, Zhao JS, Li JJ, Wang T, Cheng SQ, et al. 2010. Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway. Hepatology51:535-44
